MTNB Matinas BioPharma
- 0.1833
- +0.0007+0.38%
- 0.1808
- -0.0025-1.36%
Matinas BioPharma News
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Officer Matkovits Theresa
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Officer Hoover Thomas
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Kucinski Keith A
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Chief Technology Officer Liu Hui
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Officer Jabbour Jerome D
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Officer Ferguson James J. III
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Ende Eric J
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Corzo Kathryn Penkus
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director WIKLER MATTHEW
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director CONRAD HERBERT J
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Scibetta James S
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities-Director Giordano Natasha
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Matinas BioPharma | 4: Statement of changes in beneficial ownership of securities
Analysis
Price Target
No Data
